Hengrui Pharma(SH:600276) Ge Long Hui·2025-10-27 08:06Core Viewpoint - Heng Rui Medicine (1276.HK) experienced a 5.21% increase in stock price to 80.8 HKD following the announcement of the approval for its innovative oral diabetes medication, marking a significant milestone in the Chinese pharmaceutical market [1] Company Summary - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for its product, HR20031 tablets, which is the first self-developed oral combination therapy for type 2 diabetes in China [1] - The product is designed for adult patients with type 2 diabetes who have inadequate blood sugar control despite treatment with metformin [1] Industry Summary - According to a report from Galaxy Securities, the pharmaceutical sector has undergone a prolonged valuation adjustment but is now showing a significant structural recovery trend [1] - Public fund holdings in the pharmaceutical sector remain below historical averages, indicating potential for growth [1] - The policy environment supporting the development of commercial insurance is expected to lead to marginal improvements in payment systems by 2025, benefiting innovative drugs and medical devices [1] - The outlook for the pharmaceutical industry remains positive, with continued interest in innovative drug business development (BD) and a potential revival in pharmaceutical investment and financing [1]